CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

Zepbound will be excluded. This could complicate access to a drug that many patients cannot afford to pay for on their own. The formulary is maintained by CVS Health’s pharmacy benefits ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

The results of the head-to-head trial come days after CVS Health (NYSE:CVS)’s decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favoring Wegovy.

(Bloomberg) -- CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its members, a blow to rival Eli Lilly & Co.’s Zepbound that ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

However, CVS Health recently announced that Wegovy will be the preferred option on its list of covered drugs starting July 1, while Zepbound won't be. "We're going to need to use them all just ...